Does the CYP2C19*2 genotype affect the antiplatelet effect and clinical efficacy of clopidogrel therapy?
The CYP2C19*2 genotype is associated with reduced antiplatelet efficacy of clopidogrel and worse cardiovascular outcomes.
CYP2C19*2 genotype was associated with diminished platelet response to clopidogrel treatment and poorer cardiovascular outcomes.
Alan R. Shuldiner (2009) studied this question.